After convincing clinical trials, the compound number 606 was given the trade name "Salvarsan", a portmanteau for "saving arsenic".[1] Salvarsan was commercially introduced in 1910, and in 1913, a less toxic form, "Neosalvarsan" (Compound 914), was released in the market. These drugs became the principal treatments of syphilis until the arrival of penicillin and other novel antibiotics towards the middle of the 20th century.[2]